Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 12:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 5,231 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control/Placebo group Clear all

Conditions: Asthma, Allergic Asthma, Non-allergic Asthma
Interventions: Levocetirizine 0.5 Mg/mL Oral Solution; Drug
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 7 Years to 17 Years
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Healthy Adult Volunteers
Interventions: BMS-986090, Placebo matching with BMS-986090, Keyhole limpet hemocyanin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: Endoscopic Ultrasound (EUS), Endoscopic Retrograde Cholangiopancreatography (ERCP)
Interventions: Meperidine, Midazolam, Diphenhydramine, Promethazine; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 304 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Orange, California

Conditions: Frequent Heartburn
Interventions: Lansoprazole, placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 852 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Parsippany, New Jersey

Conditions: Graft-versus-host-disease, Ocular Graft-versus-host Disease
Interventions: Lifitegrast 5% Ophthalmic Solution, Placebo; Drug
Lead sponsor: Richard W Yee, MD; Other
Eligibility: 18 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Bellaire, Texas

Conditions: Diabetes Mellitus, Type 2, Hyperuricemia
Interventions: Low-fructose diet, isocaloric, Allopurinol, Placebo, Low-fructose, hypocaloric; Other · Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 40 Years to 75 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Episodic Migraine, Chronic Migraine
Interventions: Corabotase, Placebo, Corabotase dose A, Corabotase dose B; Biological · Other
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 670 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 68
States / cities: Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 51 more

Conditions: Asthma
Interventions: Experimental: Tezepelumab, Placebo; Biological · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 1,061 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 95
States / cities: Dothan, Alabama • Foley, Alabama • Gilbert, Arizona + 79 more

Conditions: Androgenetic Alopecia
Interventions: AH-001 or placebo; Drug
Lead sponsor: AnHorn Medicines Co. Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cognitive Impairment Associated With Schizophrenia
Interventions: MEM 3454, Placebo for MEM 3454; Drug
Lead sponsor: Memory Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 44
States / cities: Lemon Grove, California • Newport Beach, California • Oceanside, California + 29 more

Conditions: Psychology, Social, Inflammation, Defeat, Social, Interaction, Social
Interventions: Influenza vaccine, Placebo; Biological
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 35 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Chapel Hill, North Carolina

Conditions: Dental Pain
Interventions: NTC-510 capsules, Placebo Capsules, NTC-510A Capsules; Drug
Lead sponsor: NanoSHIFT LLC; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Posttraumatic Stress Disorder
Interventions: Topiramate; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 64 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Long COVID, Long COVID-19, Hypersomnia, Sleep Disturbance
Interventions: Modafinil, Modafinil Placebo, Solriamfetol, Solriamfetol Placebo, Melatonin, Melantonin Placebo, Tailored lighting (TL) Active, Tailored lighting (TL) Placebo; Drug · Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 830 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 47
States / cities: Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 31 more

Conditions: Anxiety State
Interventions: Aromatherapy, Placebo; Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 85 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Meningococcal Disease, Infections, Meningococcal
Interventions: MenACWY-CRM; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 2 Years to 10 Years
Enrollment: 715 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 19
States / cities: Birmingham, Alabama • Sacramento, California • Lake Mary, Florida + 15 more

Conditions: Hypercholesterolemia, Atherosclerosis, Statin Adverse Reaction
Interventions: Bempedoic acid, Ezetimibe, Placebo; Drug · Other
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Georgetown, Texas

Conditions: Spondylitis, Ankylosing
Interventions: Tocilizumab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 19
States / cities: Huntington Beach, California • Aventura, Florida • Miami, Florida + 16 more

Conditions: Asthma
Interventions: TEV-53275 Dose A, TEV-53275 Dose B, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 77
States / cities: Hoover, Alabama • Peoria, Arizona • Phoenix, Arizona + 62 more

Conditions: Internal Hemorrhoids
Interventions: Hydrocortisone Acetate Suppository, 25 mg (Nivagen), Placebo (Vehicle) Suppository (Nivagen); Drug
Lead sponsor: Nivagen Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Post-surgical Dental Pain
Interventions: PF-04531083, Placebo, Ibuprofen; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Revefenacin, Placebo, Formoterol; Drug
Lead sponsor: Mylan Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 12
States / cities: Miami, Florida • Orlando, Florida • Sarasota, Florida + 9 more

Conditions: Kidney Disease, Chronic
Interventions: BI 690517, Placebo matching BI 690517, Empagliflozin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 8,371 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 53
States / cities: Huntsville, Alabama • Surprise, Arizona • Beverly Hills, California + 46 more

Conditions: Acute Myocardial Infarction
Interventions: Selatogrel, Placebo; Combination Product
Lead sponsor: Viatris Innovation GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 25,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 82
States / cities: Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 73 more

Search by objective public record fields.

Characterization of the Role of Histamine in Children With Asthma

Study to Evaluate the Safety, Tolerability, PK, and PD of BMS-986090 in Healthy Subjects

Adjunct Sedatives in Endoscopic Ultrasound (EUS) and Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures

Efficacy/Safety of Lansoprazole in Patients With Frequent Nighttime Heartburn

The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host Disease

Sex-related Differences in Arterial Stiffness in Type 2 Diabetics: Role of Uric Acid

A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults

Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma

Evaluation of the Safety, Tolerability and Pharmacokinetics of AH-001 Following Topical Single and Multiple Ascending Dose Administration

Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia

Body and Social Behavior

Safety and Efficacy Study of NTC-510 to Treat Pain Following Dental Surgery of Third Molars

Safety & Efficacy Study Using Topiramate in Posttraumatic Stress Disorder

RECOVER-SLEEP: Platform Protocol

Aromatherapy Effect on Anxiety Prior to Ultrasound Guided Musculoskeletal Procedures

Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)

A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy

A Study to Test if TEV-53275 is Effective in Relieving Asthma

Evaluate Safety and Efficacy of 25 mg Hydrocortisone Acetate Suppositories in Treatment of Internal Hemorrhoids

Efficacy Of Pf-04531083 In Treating Post-Surgical Dental Pain

A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

Selatogrel Outcome Study in Suspected Acute Myocardial Infarction